Is the Mediclinic International share price a FTSE 100 bargain or a value trap?

Rupert Hargreaves considers whether FTSE 100 (INDEXFTSE: UKX) hospital giant Mediclinic International plc (LON: MDC) deserves a place in your portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The owner of Switzerland’s largest private hospital group, Mediclinic (LSE: MDC), should be one of the most defensive investments in the FTSE 100, and one of the best long-term buys for investors. But this really the case? 

Today I’m looking at whether or not this medical giant deserves a place in your portfolio. 

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Struggling for growth 

As the demand for healthcare services around the world is only expanding, Mediclinic should be one of the FTSE 100’s most predictable growth stocks. Unfortunately, that is not the case. It has been struggling to grow within its home market of South Africa due to a weak economy, while regulatory headwinds in Switzerland have also weighed on growth. 

To try and grow itself out of these issues, two years ago the company spent $2bn acquiring Al Noor Hospital, the Middle East-focused group. And it’s this business that helped the firm chalk up a 3% rise in core annual profit for the year to the end of March. Revenue for the period grew 3% in constant currency terms. Commenting on the performance, CEO Danie Meintjes said: “A key achievement was the strong second half performance in Abu Dhabi which, combined with the continued strong delivery in Dubai and the exciting expansion opportunities ahead, is laying the foundations for further growth across the Middle East division.

The company reported an overall loss of £492m thanks to non-cash impairment charges on its holding in UK private hospital provider Spire, as well as Hirslanden, Mediclinic’s Swiss hospital business. 

Growing headwinds 

As my Foolish colleague, Edward Sheldon highlighted a few weeks ago, Mediclinic’s long-term story is appealing, and after several years of floundering it finally appears as if the firm is moving in the right direction. That said, the business does have a lot to prove to the market. Earnings per share have hardly budged over the past six years, even though revenue has increased tenfold.

Management is trying to reduce costs to improve margins, but there’s lots of work to be done. The group’s operating margin fell from nearly 20% in 2012 to 13% for 2017 and it’s negative for the year ending 31 March 2018. What’s more, today’s release contains a warning that despite the opportunities for growth in the healthcare industry around the world, rising demand is “juxtaposed by lower economic growth in some regions and greater competition” as well as “an increased focus on the affordability of delivering health care which is resulting in changing care delivery models and greater regulatory oversight.” In other words, is seems Mediclinic’s outlook is cloudy, and with this being the case, I’m not convinced that the shares offer value today. 

At the time of writing, the stock trades at a forward P/E of 21.4, based on City estimates for 2019 and the shares yield 1.2%. For a business that has a patchy record of growth, and an uncertain outlook, this multiple looks too rich to me. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Woman looking at a jar of pennies
Investing Articles

I think the JD Sports share price is a bargain. Here’s why

Our writer explains why the JD Sports share price has led him to buy more for his portfolio.

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this tech stock one of the best shares to buy now?

Jabran Khan is on the hunt for the best shares to buy now for his holdings and takes a closer…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

3 top FTSE 250 shares to buy right now

I think the FTSE 250 is offering some great dividend and growth shares at the moment. And there are plenty…

Read more »

Happy retired couple on a yacht
Investing Articles

This growth stock has seen its shares pull back! Should I buy now?

When a growth stock sees its share price drop, I look carefully to see if I could pick up a…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How to identify the best income shares like this one

Income shares vary in quality but this approach keeps me from making some of the worst howlers with dividend investing.

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

If I’d invested £1k in Tesla shares a year ago, here’s how much I’d have now

If Jon Smith had bought Tesla shares a year ago, he'd be in profit. But he has some concerns for…

Read more »

Twenty pound notes in back pocket of jeans
Investing Articles

Should I buy tobacco shares now for big dividends?

After a possible setback for electronic cigarettes, our writer explains why he would still buy tobacco shares for his income…

Read more »

a couple embrace in front of their new home
Investing Articles

3 FTSE shares I’m buying with the Help to Build scheme!

Last week, the government launched a new, Help to Build scheme. So, here are three FTSE shares that could benefit…

Read more »